ORGOVYX is the only oral once-a-day GnRH receptor antagonist for advanced prostate cancer1,2

DIVE INTO ORGOVYX

Make ORGOVYX
your first-choice
ADT for advanced prostate cancer
See how changes to
Medicare Part D
could impact your
patients
RECOMMENDED BY NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES®)4*

NCCN Guidelines® recommend relugolix (ORGOVYX) as a NCCN Category 2A treatment option for patients with advanced prostate cancer

Some recommendations may fall outside of the ORGOVYX US Prescribing Information.

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

A Category 2A recommendation is based on lower-level evidence and indicates uniform NCCN consensus that the intervention is appropriate.4

Testosterone
can be
controlled
Throughout
the dive
PRIMARY ENDPOINT

SUSTAINED
TESTOSTERONE SUPPRESSION TO <50 ng/dL.1

96.7%

(95% CI: 94.9-97.9) of men achieved and maintained testosterone suppression to <50 ng/dL from Day 29 through Week 48 with ORGOVYX (n=622)1

88.8% (95% CI: 84.6-91.8) of men treated with leuprolide achieved and maintained testosterone suppression to <50 ng/dL from Day 29 through Week 481

See the efficacy data
HERO STUDY DESIGN

THE HERO STUDY was a multinational, randomized, open-label, phase 3 trial in 930 men with aPC. Key inclusion criteria included men with aPC defined as biochemical prostate-specific antigen (PSA) or clinical relapse following local primary intervention with curative intent, newly diagnosed castration-sensitive metastatic disease, or advanced localized disease unlikely to be cured by local primary intervention, requiring at least 1 year of androgen deprivation therapy (ADT), ECOG 0/1. Patients were randomized 2:1 to receive ORGOVYX (360 mg on the first day followed by daily doses of 120 mg orally [n=622]) or leuprolide acetate (22.5 mg injection§) for 48 weeks.1,2

CI=confidence interval; ECOG=Eastern Cooperative Oncology Group.

The castration rate of the subgroup of patients receiving 22.5 mg leuprolide (n=264) was 88.0% (95% CI: 83.4%-91.4%).1

§11.25 mg in Japan and Taiwan per local guidelines subcutaneously every 3 months [n=308]. 11.25 mg is a dosage regimen that is not recommended for aPC in the United States.1

Please see additional information about ORGOVYX throughout this website.

ESTABLISHED SAFETY

The most common adverse events during treatment with ORGOVYX (≥10%) in the study were hot flush, musculoskeletal pain, fatigue, constipation, and diarrhea.1

ESTABLISHED SAFETY

The most common adverse events during treatment with ORGOVYX (≥10%) in the study were hot flush, musculoskeletal pain, fatigue, constipation, and diarrhea.1

Review ORGOVYX safety data from the HERO study

Watch Dr Neal D. Shore
and Dr Eleni Efstathiou
talk about ORGOVYX

Please see full Prescribing Information and Important Safety Information for ORGOVYX.

With over half a million prescriptions filled, consider ORGOVYX for
your patients with aPC3||

ORGOVYX NATIONAL COVERAGE
99% of Medicare patients are covered for ORGOVYX with no step therapy
92% of commercial patients are covered for ORGOVYX
 
SEE FORMULARY COVERAGE
IN YOUR AREA

||Based on internal demand data (SD, SP, and PAP) as of June 2024. Total prescriptions since FDA approval is estimated based on the shipping quantity of ORGOVYX, with each bottle equivalent to one prescription.3

This coverage information is provided for informational purposes only; individual plans vary, and this may not include all plans. Sumitomo Pharma America and Pfizer make no representation or guarantee concerning coverage or reimbursement for ORGOVYX; please check with individual payers for plan-specific coverage and reimbursement information and requirements. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced. This information is subject to change without notice. Data on file. Formulary data are provided by MMIT, LLC, as of May 2024. Transaction data are provided by SHS database as of May 2024.